vs
ICU MEDICAL INC（ICUI）与KRONOS WORLDWIDE INC（KRO）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是KRONOS WORLDWIDE INC的1.3倍（$540.7M vs $418.3M），ICU MEDICAL INC净利率更高（-2.9% vs -19.8%，领先16.9%），KRONOS WORLDWIDE INC同比增速更快（-1.1% vs -14.1%），KRONOS WORLDWIDE INC自由现金流更多（$81.9M vs $36.0M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -6.5%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
克罗诺斯全球（原克罗诺斯公司）是一家美国跨国企业，总部位于美国马萨诸塞州洛厄尔，专注于提供劳动力管理与人力资本管理云服务，在全球拥有超过6000名员工，是该领域知名的服务提供商。
ICUI vs KRO — 直观对比
营收规模更大
ICUI
是对方的1.3倍
$418.3M
营收增速更快
KRO
高出13.0%
-14.1%
净利率更高
ICUI
高出16.9%
-19.8%
自由现金流更多
KRO
多$45.9M
$36.0M
两年增速更快
ICUI
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $418.3M |
| 净利润 | $-15.7M | $-82.8M |
| 毛利率 | 37.5% | -0.9% |
| 营业利润率 | 1.0% | -15.1% |
| 净利率 | -2.9% | -19.8% |
| 营收同比 | -14.1% | -1.1% |
| 净利润同比 | 34.0% | -527.3% |
| 每股收益（稀释后） | $-0.63 | $-0.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIKRO
| Q4 25 | $540.7M | $418.3M | ||
| Q3 25 | $537.0M | $456.9M | ||
| Q2 25 | $548.9M | $494.4M | ||
| Q1 25 | $604.7M | $489.8M | ||
| Q4 24 | $629.8M | $423.1M | ||
| Q3 24 | $589.1M | $484.7M | ||
| Q2 24 | $596.5M | $500.5M | ||
| Q1 24 | $566.7M | $478.8M |
净利润ICUIKRO
| Q4 25 | $-15.7M | $-82.8M | ||
| Q3 25 | $-3.4M | $-37.0M | ||
| Q2 25 | $35.3M | $-9.2M | ||
| Q1 25 | $-15.5M | $18.1M | ||
| Q4 24 | $-23.8M | $-13.2M | ||
| Q3 24 | $-33.0M | $71.8M | ||
| Q2 24 | $-21.4M | $19.5M | ||
| Q1 24 | $-39.5M | $8.1M |
毛利率ICUIKRO
| Q4 25 | 37.5% | -0.9% | ||
| Q3 25 | 37.4% | 10.3% | ||
| Q2 25 | 37.9% | 12.7% | ||
| Q1 25 | 34.7% | 21.8% | ||
| Q4 24 | 36.1% | 20.4% | ||
| Q3 24 | 34.8% | 20.9% | ||
| Q2 24 | 34.8% | 20.0% | ||
| Q1 24 | 32.7% | 14.9% |
营业利润率ICUIKRO
| Q4 25 | 1.0% | -15.1% | ||
| Q3 25 | 2.6% | -4.2% | ||
| Q2 25 | 1.9% | 1.5% | ||
| Q1 25 | 2.1% | 7.8% | ||
| Q4 24 | 6.0% | 6.8% | ||
| Q3 24 | 1.4% | 8.0% | ||
| Q2 24 | 1.3% | 7.2% | ||
| Q1 24 | -1.9% | 4.1% |
净利率ICUIKRO
| Q4 25 | -2.9% | -19.8% | ||
| Q3 25 | -0.6% | -8.1% | ||
| Q2 25 | 6.4% | -1.9% | ||
| Q1 25 | -2.6% | 3.7% | ||
| Q4 24 | -3.8% | -3.1% | ||
| Q3 24 | -5.6% | 14.8% | ||
| Q2 24 | -3.6% | 3.9% | ||
| Q1 24 | -7.0% | 1.7% |
每股收益（稀释后）ICUIKRO
| Q4 25 | $-0.63 | $-0.72 | ||
| Q3 25 | $-0.14 | $-0.32 | ||
| Q2 25 | $1.43 | $-0.08 | ||
| Q1 25 | $-0.63 | $0.16 | ||
| Q4 24 | $-0.97 | $-0.11 | ||
| Q3 24 | $-1.35 | $0.62 | ||
| Q2 24 | $-0.88 | $0.17 | ||
| Q1 24 | $-1.63 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $33.2M |
| 总债务越低越好 | — | $557.4M |
| 股东权益账面价值 | $2.1B | $751.1M |
| 总资产 | $4.1B | $1.8B |
| 负债/权益比越低杠杆越低 | — | 0.74× |
8季度趋势，按日历期对齐
现金及短期投资ICUIKRO
| Q4 25 | — | $33.2M | ||
| Q3 25 | — | $27.7M | ||
| Q2 25 | — | $18.9M | ||
| Q1 25 | — | $20.5M | ||
| Q4 24 | $308.6M | $106.7M | ||
| Q3 24 | $312.5M | $94.8M | ||
| Q2 24 | $302.6M | $133.8M | ||
| Q1 24 | $251.4M | $120.7M |
总债务ICUIKRO
| Q4 25 | — | $557.4M | ||
| Q3 25 | — | $626.2M | ||
| Q2 25 | — | $589.3M | ||
| Q1 25 | — | $557.2M | ||
| Q4 24 | — | $507.4M | ||
| Q3 24 | — | $554.3M | ||
| Q2 24 | — | $423.7M | ||
| Q1 24 | — | $426.9M |
股东权益ICUIKRO
| Q4 25 | $2.1B | $751.1M | ||
| Q3 25 | $2.1B | $804.7M | ||
| Q2 25 | $2.1B | $846.8M | ||
| Q1 25 | $2.0B | $847.0M | ||
| Q4 24 | $2.0B | $817.0M | ||
| Q3 24 | $2.0B | $847.4M | ||
| Q2 24 | $2.0B | $774.6M | ||
| Q1 24 | $2.1B | $774.4M |
总资产ICUIKRO
| Q4 25 | $4.1B | $1.8B | ||
| Q3 25 | $4.1B | $1.9B | ||
| Q2 25 | $4.1B | $1.9B | ||
| Q1 25 | $4.2B | $1.9B | ||
| Q4 24 | $4.2B | $1.9B | ||
| Q3 24 | $4.3B | $1.9B | ||
| Q2 24 | $4.3B | $1.7B | ||
| Q1 24 | $4.3B | $1.7B |
负债/权益比ICUIKRO
| Q4 25 | — | 0.74× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.62× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $92.1M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $81.9M |
| 自由现金流率自由现金流/营收 | 6.6% | 19.6% |
| 资本支出强度资本支出/营收 | 4.6% | 2.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | $-40.4M |
8季度趋势，按日历期对齐
经营现金流ICUIKRO
| Q4 25 | $60.6M | $92.1M | ||
| Q3 25 | $56.7M | $-7.9M | ||
| Q2 25 | $11.2M | $20.7M | ||
| Q1 25 | $51.3M | $-102.4M | ||
| Q4 24 | $40.2M | $49.3M | ||
| Q3 24 | $36.1M | $28.3M | ||
| Q2 24 | $82.0M | $38.2M | ||
| Q1 24 | $45.8M | $-43.3M |
自由现金流ICUIKRO
| Q4 25 | $36.0M | $81.9M | ||
| Q3 25 | $27.6M | $-17.4M | ||
| Q2 25 | $-8.5M | $9.5M | ||
| Q1 25 | $36.7M | $-114.4M | ||
| Q4 24 | $16.1M | $37.0M | ||
| Q3 24 | $16.2M | $19.2M | ||
| Q2 24 | $62.5M | $34.8M | ||
| Q1 24 | $29.9M | $-48.0M |
自由现金流率ICUIKRO
| Q4 25 | 6.6% | 19.6% | ||
| Q3 25 | 5.1% | -3.8% | ||
| Q2 25 | -1.5% | 1.9% | ||
| Q1 25 | 6.1% | -23.4% | ||
| Q4 24 | 2.6% | 8.7% | ||
| Q3 24 | 2.7% | 4.0% | ||
| Q2 24 | 10.5% | 7.0% | ||
| Q1 24 | 5.3% | -10.0% |
资本支出强度ICUIKRO
| Q4 25 | 4.6% | 2.4% | ||
| Q3 25 | 5.4% | 2.1% | ||
| Q2 25 | 3.6% | 2.3% | ||
| Q1 25 | 2.4% | 2.4% | ||
| Q4 24 | 3.8% | 2.9% | ||
| Q3 24 | 3.4% | 1.9% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 2.8% | 1.0% |
现金转化率ICUIKRO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 1.96× | ||
| Q1 24 | — | -5.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
KRO
暂无分部数据
